DE69433760D1 - Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält - Google Patents
Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthältInfo
- Publication number
- DE69433760D1 DE69433760D1 DE69433760T DE69433760T DE69433760D1 DE 69433760 D1 DE69433760 D1 DE 69433760D1 DE 69433760 T DE69433760 T DE 69433760T DE 69433760 T DE69433760 T DE 69433760T DE 69433760 D1 DE69433760 D1 DE 69433760D1
- Authority
- DE
- Germany
- Prior art keywords
- jeryl
- lynn
- virus
- tribe
- mumps vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0015—Combination vaccines based on measles-mumps-rubella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18761—Methods of inactivation or attenuation
- C12N2760/18762—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939323820A GB9323820D0 (en) | 1993-11-19 | 1993-11-19 | Vaccine |
| GB9323820 | 1993-11-19 | ||
| GB9406480A GB9406480D0 (en) | 1994-03-31 | 1994-03-31 | Vaccine |
| GB9406480 | 1994-03-31 | ||
| PCT/EP1994/003801 WO1995014083A1 (en) | 1993-11-19 | 1994-11-15 | Vaccine against mumps containing a jeryl-lynn virus strain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69433760D1 true DE69433760D1 (de) | 2004-06-09 |
| DE69433760T2 DE69433760T2 (de) | 2005-05-12 |
Family
ID=26303889
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1994633760 Pending DE122007000003I1 (de) | 1993-11-19 | 1994-11-15 | Gegen mumps Impfstoff, der ein Virus des Jeryl-Lynn Stammes enthält |
| DE122007000003C Active DE122007000003I2 (de) | 1993-11-19 | 1994-11-15 | Gegen mumps impfstoff, der ein virus des jeryl-lynn stammes enthält |
| DE69433760T Expired - Lifetime DE69433760T2 (de) | 1993-11-19 | 1994-11-15 | Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1994633760 Pending DE122007000003I1 (de) | 1993-11-19 | 1994-11-15 | Gegen mumps Impfstoff, der ein Virus des Jeryl-Lynn Stammes enthält |
| DE122007000003C Active DE122007000003I2 (de) | 1993-11-19 | 1994-11-15 | Gegen mumps impfstoff, der ein virus des jeryl-lynn stammes enthält |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US6024962A (de) |
| EP (2) | EP0729509B1 (de) |
| JP (1) | JPH09504954A (de) |
| KR (1) | KR100362051B1 (de) |
| CN (2) | CN1150819A (de) |
| AT (1) | ATE266090T1 (de) |
| AU (1) | AU687922B2 (de) |
| CA (1) | CA2176929C (de) |
| CY (2) | CY2540B1 (de) |
| DE (3) | DE122007000003I1 (de) |
| DK (1) | DK0729509T3 (de) |
| ES (1) | ES2219658T3 (de) |
| HK (1) | HK1012421A1 (de) |
| LU (1) | LU91458I2 (de) |
| NL (1) | NL300336I2 (de) |
| NZ (1) | NZ276102A (de) |
| PT (1) | PT729509E (de) |
| SG (1) | SG52780A1 (de) |
| SI (1) | SI0729509T1 (de) |
| WO (1) | WO1995014083A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2176929C (en) | 1993-11-19 | 2002-04-30 | Nigel Maurice Harford | Vaccine against mumps containing a jeryl-lynn virus strain |
| JP2003506039A (ja) * | 1999-08-02 | 2003-02-18 | ワイス | ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー |
| MX2017012389A (es) * | 2015-03-27 | 2018-09-19 | Cadila Healthcare Ltd | Vacuna del virus de la parotiditis recombinante jeryl lynn2. |
| RU2750818C1 (ru) * | 2020-11-19 | 2021-07-05 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова | Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения |
| CN114457046A (zh) * | 2022-02-16 | 2022-05-10 | 科兴（大连）疫苗技术有限公司 | 一种稀释法传代纯化腮腺炎病毒的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3555149A (en) | 1968-07-05 | 1971-01-12 | Merck & Co Inc | Mumps vaccine and its preparation |
| US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| JP3026029B2 (ja) * | 1991-04-26 | 2000-03-27 | 財団法人阪大微生物病研究会 | 組換え水痘ウイルスとその作製法 |
| CA2176929C (en) | 1993-11-19 | 2002-04-30 | Nigel Maurice Harford | Vaccine against mumps containing a jeryl-lynn virus strain |
-
1994
- 1994-11-15 CA CA002176929A patent/CA2176929C/en not_active Expired - Lifetime
- 1994-11-15 CN CN94194807A patent/CN1150819A/zh active Pending
- 1994-11-15 WO PCT/EP1994/003801 patent/WO1995014083A1/en active IP Right Grant
- 1994-11-15 DK DK95900751T patent/DK0729509T3/da active
- 1994-11-15 ES ES95900751T patent/ES2219658T3/es not_active Expired - Lifetime
- 1994-11-15 DE DE1994633760 patent/DE122007000003I1/de active Pending
- 1994-11-15 SG SG1996009415A patent/SG52780A1/en unknown
- 1994-11-15 JP JP7514221A patent/JPH09504954A/ja active Pending
- 1994-11-15 EP EP95900751A patent/EP0729509B1/de not_active Expired - Lifetime
- 1994-11-15 AU AU81441/94A patent/AU687922B2/en not_active Expired
- 1994-11-15 DE DE122007000003C patent/DE122007000003I2/de active Active
- 1994-11-15 NZ NZ276102A patent/NZ276102A/en not_active IP Right Cessation
- 1994-11-15 AT AT95900751T patent/ATE266090T1/de active
- 1994-11-15 US US08/649,654 patent/US6024962A/en not_active Expired - Lifetime
- 1994-11-15 CN CN2010101643698A patent/CN101948816A/zh active Pending
- 1994-11-15 EP EP04075732A patent/EP1484391A1/de not_active Withdrawn
- 1994-11-15 DE DE69433760T patent/DE69433760T2/de not_active Expired - Lifetime
- 1994-11-15 SI SI9430462T patent/SI0729509T1/xx unknown
- 1994-11-15 PT PT95900751T patent/PT729509E/pt unknown
- 1994-11-15 KR KR1019960702618A patent/KR100362051B1/ko not_active IP Right Cessation
-
1998
- 1998-12-16 HK HK98113644A patent/HK1012421A1/xx unknown
-
2000
- 2000-12-22 US US09/748,343 patent/US20020018784A1/en not_active Abandoned
-
2002
- 2002-08-07 US US10/213,965 patent/US6656476B2/en not_active Expired - Fee Related
-
2003
- 2003-11-03 US US10/699,751 patent/US6899884B2/en not_active Expired - Fee Related
-
2005
- 2005-09-30 CY CY0500054A patent/CY2540B1/xx unknown
-
2008
- 2008-02-12 NL NL300336C patent/NL300336I2/nl unknown
- 2008-02-19 CY CY2008005C patent/CY2008005I2/el unknown
- 2008-06-24 LU LU91458C patent/LU91458I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE295895T1 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| ATE267211T1 (de) | Impfstoff gegen hpv | |
| ATE272113T1 (de) | Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma | |
| NO20001768L (no) | Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav | |
| DE69632235D1 (de) | Newcastle-Krankheitsvirus-Kombinationsimpfstoff | |
| ATE328068T1 (de) | Papillomavirus vakzine | |
| NO912825D0 (no) | Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper. | |
| NL300336I1 (nl) | Vaccin tegen de bof dat een jeryl-lynn virusstam bevat | |
| DE69432730D1 (de) | Rekombinante Adenovirus-Vakzinen | |
| DE69637435D1 (de) | Saponin-zusammensetzungen und deren verwendung | |
| ATE530563T1 (de) | Rekombinante proteine einer pakistanischen hepatitis e variante und ihre verwendung in diagnoseverfahren und impfungen | |
| ATE177010T1 (de) | Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie | |
| DE9117146U1 (de) | Impfstoffe gegen virale Antigene |